Newron Shareholders Authorize Allocation of Additional Shares to Support Multiple Clinical Programs

Milan, Italy - 24 March 2015 - Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel Central Nervous System (CNS) and pain therapies, announced that shareholders today authorized the Company to allocate up to 1.3 million shares to raise capital.

"Newron is committed to bringing much needed new therapies to patients with CNS diseases," said Stefan Weber, CEO of Newron. "With EU marketing authorization in place for Xadago® (safinamide) for Parkinson's disease (PD) and the NDA accepted by the U.S. FDA, we are focused on advancing our programs for Rett syndrome, schizophrenia, treatment resistant PD and amyotrophic lateral sclerosis (ALS). The authorization for this share allocation enables us to raise funds to advance these clinical programs."

At the Shareholders' Meeting held today, 24 March 2015 in Bresso (MI), Italy, shareholders authorized a share capital increase for payment, severable, with exclusion of the option right, for maximum nominal Euro 260,850, and therefore, for maximum n. 1,304,250 Newron Pharmaceuticals S.p.A. ordinary shares and, in any event, within the limits of the 10% of the share capital in accordance with article 2441, paragraph fourth, second part, of the Italian Civil Code and with article 6 of Company's By-Laws. Shareholders also authorized a second share capital increase for payment, severable, with exclusion of the option right, in accordance with article 2441, paragraphs 5 and 8, of the Italian Civil Code, for maximum nominal Euro 80,000, and therefore, for maximum n. 400,000 Newron Pharmaceuticals S.p.A. ordinary shares, nominal value Euro 0.20 each, to serve one or more stock incentive plans.

At the Shareholders' meeting, 33.9% of Newron's total capital of 13,092,850 shares were represented. Shareholders also approved the Company's financial statements as of 31 December 2014.

Prof. Hanns Möhler, Non-executive Director and Chairman of Newron's R&D Committee, has declared his intention to retire from Newron's Board of Directors for personal reasons, effective post today's Shareholders' Meeting. Prof. Möhler has been a Director on Newron's Board since 2008. Ulrich Köstlin, Chairman of the Board of Directors, said: "Hanns' commitment and support has been of material relevance to the positive turn at Newron. The Board and team express their appreciation for Hanns and his significant contributions that he has offered the Company over these seven years." Professor Möhler will support Newron's further development as a scientific consultant to the Company.

About Newron Pharmaceuticals

Newron (SIX: NWRN) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain. The Company is headquartered in Bresso near Milan, Italy. Marketing authorization in the EU for Xadago® (safinamide) was granted by the EU Commission in February 2015, following the recommendation by the Committee for Medicinal Products for Human Use (CHMP) to approve the compound in the EU on Dec. 19, 2014. The New Drug Application NDA to the U.S. FDA, as informed early March, has been accepted for filing, after being re-submitted by Newron on Dec. 26, 2014. In March 2014, Zambon, a partner of Newron, submitted a MAA to Swissmedic. Zambon has the rights to develop and commercialize safinamide globally, excluding Japan and other key Asian territories where Meiji Seika has the rights to develop and commercialize the compound. Newron's additional projects are based on highly promising treatments for rare disease patients and are at various stages of clinical development, including sarizotan for patients with Rett syndrome, sNN0031 for patients with Parkinson's disease, non-responsive to oral drug treatments, sNN0029 for patients with ALS and ralfinamide for patients with specific rare pain indications. Newron is also developing NW-3509 as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.

For more information